Peer reviewed - observational study - humansThe Covid pandemic disrupted children’s ability to self-regulate - according to ...
Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not ...
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
UCB obtains worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseasesDeal ...
LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare ProvidersHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc.
Innovation Investment Capital Limited Partnership (IIC), the Cardiff Capital Region (CCR) backed fund, and the Development Bank of Wales today announced a joint equity investment in Antiverse Limited, ...
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...
ImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer Center
The company also announced a strategic investment from Leonardo DiCaprioSINGAPORE & SAN DIEGO--(BUSINESS WIRE)--ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is ...
Astra Zeneca - Future Biogas: first anniversary of unsubsidised biomethane plant with carbon capture
In February 2025, Future Biogas and AstraZeneca commissioned the UK’s first unsubsidised biomethane plant at Gonerby Moor in Lincolnshire. One year on, Future Biogas CEO Philipp Lukas explains how the ...
Adhesives expert Intertronics has released its Endurawipe™ Biodegradable 70/30 IPA Wipes, a new industrial cleaning wipe made from 100 per cent eucalyptus-derived viscose that breaks down within 12 ...
CNX Therapeutics Limited ("CNX Therapeutics"), a European specialty pharmaceutical company, today announced the appointment of Erin Federman as a non-executive director, with effect from 1 March 2026.
Joint offering helps life sciences companies align launch strategy and commercial decisions across global markets REDWOOD CITY, Calif. — March 2, 2026 — Model N, the leading end-to-end ...
Innovative AI-powered architecture, embedded NVIDIA technology, and immediate provisioning of secure workspaces help accelerate research and innovation Zurich – 3 March 2026 - BC Platforms, a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results